Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Ledergerber B, Egger M, Opravil M.
et al. Clinical progression and virological failure on highly active antiretroviral
therapy in HIV-1 patients: a prospective cohort study. Lancet.1999;353:863-868.
Egger M, Hirschel B, Francioli P.
et al. Impact of new antiretroviral combination therapies in HIV infected
patients in Switzerland: prospective multicentre study. BMJ.1997;315:1194-1199.
Michelet C, Arvieux C, François C.
et al. Opportunistic infections occurring during highly active antiretroviral
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction
after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet.1998;351:1682-1686.
Bisset LR, Cone RW, Huber W.
et al. Highly active antiretroviral therapy during early HIV infection reverses
T-cell activation and maturation abnormalities. AIDS.1998;12:2115-2123.
Autran B, Carcelain G, Li TS.
et al. Positive effects of combined antiretroviral therapy on CD4+ T cell
homeostasis and function in advanced HIV disease. Science.1997;277:112-116.
Carr A, Cooper DA. Cytomegalovirus retinitis after initiation of highly active antiretroviral
Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas
complicating human immunodeficiency virus infection in a patient receiving
highly active antiretroviral therapy. Clin Infect Dis.1998;26:1008-1009.
Race EM, Adelson-Mitty J, Kriegel GR.
et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor
therapy in patients with advanced HIV-1 disease. Lancet.1998;351:252-255.
Karavellas MP, Lowder CY, Macdonald C, Avila Jr CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis:
a new syndrome. Arch Ophthalmol.1998;116:169-175.
Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination
antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol.1998;125:292-300.
Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet.1998;351:228-230.
Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline
characteristics. Soz Praventivmed.1994;39:387-394.
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41:1-19.
Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in patients
with HIV infection. Drugs.1998;55:461-486.
Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika.1982;69:239-241.
Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with
potent antiretroviral therapy: prospective cohort study. BMJ.1999;319:23-24.
Martinez E, Gatell J, Moran Y.
et al. High incidence of herpes zoster in patients with AIDS soon after therapy
with protease inhibitors. Clin Infect Dis.1998;27:1510-1513.
Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral
therapy in AIDS patients treated for extrapulmonary tuberculosis: treatment
with corticosteroids. Am J Med.1999;106:371-372.
Miller V, Mocroft A, Reiss P.
et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy,
and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med.1999;130:570-577.
Feinberg J. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia [editorial]. Lancet.1999;353:1287.
Chene G, Binquet C, Moreau JF.
et al. Changes in CD4+ cell count and the risk of opportunistic infection
or death after highly active antiretroviral treatment. AIDS.1998;12:2313-2320.
Weverling GJ, Mocroft A, Ledergerber B.
et al. Discontinuation of Pneumocystis carinii pneumonia
prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet.1999;353:1293-1298.
Furrer H, Egger M, Opravil M.
et al. Discontinuation of primary prophylaxis against Pneumocystis
carinii pneumonia in HIV-1 infected adults treated with combination
antiretroviral therapy. N Engl J Med.1999;340:1301-1306.
Piketty C, Castiel P, Belec L.
et al. Discrepant responses to triple combination antiretroviral therapy in
advanced HIV disease. AIDS.1998;12:745-750.
Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with
highly active antiretroviral therapy (HAART). Lancet.1998;351:723-724.
Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science.1998;280:1871-1873.
Hengge UR, Goos M, Esser S.
et al. Randomized, controlled phase II trial of subcutaneous interleukin-2
in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS.1998;12:F225-F234.
Bassetti S, Battegay M, Furrer H.
et al. Why is highly active antiretroviral therapy (HAART) not prescribed
or discontinued? J Acquir Immune Defic Syndr.1999;21:114-119.
Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations
of the International AIDS Society-USA Panel. JAMA.1998;280:78-86.
Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N Engl J Med.1998;338:906-908.